TEST:

Aptima® HPV Assay

Our findings indicate that while cytomorphology alone is not fully adequate for precise hrHPV typing, it may offer supportive value, particularly in settings where HPV testing is not readily available.

Following resuspension, samples showed high stability, with reproducibility ranging from (89.4%-100%). These data support the optimisation of laboratory workflows, acceptance criteria, and standardised HPV self-sampling protocols.

A previous negative Aptima mRNA HPV test confers a protective effect for CIN2+/CIN3+ in mRNA HPV-positive women with minor cytological changes. The adjusted risks impact patient management, decreasing colposcopy referrals.

Bacterial vaginosis, high Nugent score, and leukocyte esterase positivity were independently associated with HPV infection, whereas HPV vaccination offered protection. These results underscore the value of integrating vaginal microecological assessment and HPV testing into routine prenatal care.

"Hologic, Inc...announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer."